VIVES Stock Overview
Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Vivesto AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.28 |
52 Week High | SEK 0 |
52 Week Low | SEK 0 |
Beta | 0.63 |
11 Month Change | n/a |
3 Month Change | n/a |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 0% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
VIVES | GB Biotechs | GB Market | |
---|---|---|---|
7D | n/a | -0.1% | 0.3% |
1Y | n/a | -18.7% | 11.6% |
Return vs Industry: Insufficient data to determine how VIVES performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how VIVES performed against the UK Market.
Price Volatility
VIVES volatility | |
---|---|
VIVES Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.3% |
Market Average Movement | 4.6% |
10% most volatile stocks in GB Market | 9.7% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: VIVES has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VIVES's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 6 | Erik Kinnman | www.vivesto.com |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto AB Fundamentals Summary
VIVES fundamental statistics | |
---|---|
Market cap | SEK 145.27m |
Earnings (TTM) | -SEK 116.77m |
Revenue (TTM) | SEK 6.61m |
22.0x
P/S Ratio-1.2x
P/E RatioIs VIVES overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VIVES income statement (TTM) | |
---|---|
Revenue | SEK 6.61m |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 6.61m |
Other Expenses | SEK 123.38m |
Earnings | -SEK 116.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | -0.22 |
Gross Margin | 100.00% |
Net Profit Margin | -1,766.05% |
Debt/Equity Ratio | 0% |
How did VIVES perform over the long term?
See historical performance and comparison